ASSOCIATOIN OF CHINESE AMERICANS IN CANCER RESEARCH

Association of Chinese Americans in Cancer Research Newsletter

Volume 2, Issue 9 August 2022

Inside this issue:

President's welcome message

Dear ACACR members and friends,

It is great that we are going back to normal and getting closer to each other as a group. I would like to take this opportunity to highlight several recent events of ACACR.

We finally had our first in-person annual meeting since the beginning of pandemic at AACR on April 9, 2022 in New Orleans. Drs. Hua Lu, Jiaoti Huang, and Yang Liu gave excellent keynote talks on their unique perspectives on basic, clinical and translational cancer research as well as leadership experience. The social gathering featured reunion of many old friends and long-time collaborators. On behalf of ACACR, I would like to thank Drs. Hua Lu, Zongbin You, and all local volunteers at Tulane Medical School for helping us put together this wonderful event, and Drs. Yang Liu and Pan Zheng from OncoC4 for their sponsorship.

In this summer, we have organized the Third ACACR Virtual Seminar Series, featuring presentations by 21 speakers including 3 journal editors. The seminar we had on July 22, 2022 was participated by a record number of 266 people. This Seminar Series has become an excellent platform for us to learn cutting-edge science and exchange new ideas.

In this June, we had our biannual election. ACACR members exhibited great interests and enthusiasm to serve and vote. Congratulations to Drs. Gen-Sheng Feng, Boyi Gan, and Lanjing Zhang, who will serve us as the next ACACR President, President-Elect, and Treasurer, respectively!

ACACR has continued to work with other organizations such as SCBA (Society of Chinese Bioscientists in America) to support the community of Chinese American scientists as a whole. Our affiliated journal *Genes & Diseases* has been doing quite well and received improved impact factor this year.

I look forward to working with you to further improve ACACR. Wish you and your families a great summer!

Lin Zhang, PhD

President, ACACR
Professor
UMPC Hillman Cancer Center
Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213-1863

Final Program of the 2022 ACACR annual meeting (see also online)

When: 3:00 – 8:00 pm, Saturday, April 09, 2022

Where: First Floor Auditorium, 1430 Tulane Ave., New Orleans, LA 70112

Agenda

3:00 – 3:05 Welcome and introduction by Dr. Erxi Wu

3:05 – 3:15 ACACR Presidential Address by Dr. Lin Zhang

3:15 – 3:45 Keynote Address: Hua Lu, PhD, Professor and Chairman, Department of Biochemistry, Tulane University School of Medicine

3:45 –4:15 Keynote Address: Jiaoti Huang, MD, PhD, Professor and Chairman, Department of Pathology, Duke University School of Medicine

4:15 –4:45 Keynote Address: Yang Liu, PhD, Chairman, CEO and CSO, OncoC4, Inc.

4:45 – 5:05 ACACR Cooperate member representatives

5:05 – 5:15 AACR representative: Dr. Frédéric Biemar, Director of International Affairs

5:15 – 5:20 ACACR annual financial report by Dr. Yong Li

5:20 – 5:25 Update on ACACR Publication/newsletters: Drs. Zhenghe Wang and Lanjing Zhang

5:25 – 5:30 Closing Remarks/Future plans by Gloria Su

5:30 – 6:00 Networking/Social

6:00 – 8:00 Dinner/Social

Organizing committee:

Gensheng Feng, PhD; Tongchuan He, MD, PhD; Lin Zhang, PhD; Shi-Yuan Cheng, PhD; Zhenkun Lou, PhD; Gloria Su, PhD; Yong Li, PhD; Erxi Wu, PhD

Dr Lin Zhang, ACACR President

Dr Erix Wu, ACACR General Secretary

Dr Hua Lu, ACACR Keynote Speaker

Dr Jiaoti Huang, ACACR Keynote Speaker

Dr Shi-Yuan Cheng, ACACR Past President

Dr. Frédéric Biemar, AACR Director of International Affairs



Dr Yong Li, ACACR Treasurer



Dr Zhenghe John Wang, Deputy Editor-in-Chief, *Gens& Dis*

Dr Gloria Su, ACACR President-elect

Audience

Photo credits: Drs. Wu, Xi, and Zhang

Election of ACACR Officers

6/7/2022 Announcement of the election

It is time for us to elect new ACACR executives as Dr. Gloria Su took a new NIH position and the current team has been over stretched. Please consider nominating yourself or someone else for:

1) ACACR President-Elect
2) ACACR Treasurer

Please send CV or nominee's name to Dr. Erxi Wu via WeChat or email (erxiwu@gmail.com) by June 15, 2022. Thanks.

ACACR Executives

7/4/2022 Announcement of the candidates

Thanks to the members' enthusiastic participation, we have 3 candidates for President-elect and Incoming President, and 2 candidates for Treasurer.

President and President-elect Candidates (Choose 2):

Gensheng Feng (UCSD), Boyi Gan (MD Anderson), Lily Yang (Emory)

Treasurer Candidates (Choose 1):

Wei Xu (Wisconsin Madison), Lanjing Zhang (Rutgers/Princeton)

The following are the biosketches of the candidates. We will use the Google form for sending ballots and conducting election. See the ballot link below. Please vote after signing in with your Google/Gmail account. The voting deadline is 20:00 EDT, July 15, 2022.

https://docs.google.com/forms/d/1znBztAveQLbEyEwr9ogzunejpWCbp-C_ehbjjy2xG8g/edit

7/17/2022 Announcement of the election results

Thank you for your active participation in our recent elections, and even more thanks to several candidates who stood up and were willing to serve the community of Chinese scholars during their busy schedules. Now that the election is over, the result is Gensheng Feng was elected as President (now to end of 2022, as President-elect), Boyi Gan as President-elect. and Lanjing Zhang as Treasurer. The terms are all 01/01/2023-12/31/2024, for two years。

Congratulations! Many thanks to all candidates for your participation!

Members' Research Highlights

Dr. **Taosheng Chen** at St. Jude Children's Research Hospital discovered unexpected functional cross-talk among nuclear receptor PXR, CAR, and RXR, thereby opening new perspectives on elucidating their role and designing potential approaches to target them. This study was published in ***Nuclear Acid Research***: https://academic.oup.com/nar/article/50/6/3254/6536889?searchresult=1

Dr. **Deliang Guo** at the Ohio State University discovered that sterol regulatory element-binding proteins (SREBPs) play a central role in lipid metabolism through the regulation of ammonia release from glutamine. Moreover, he further demonstrated that SCAP is a critical sensor of glutamine, glucose, and sterol levels. This study was published as a cover article in ***Nature Metabolism***: https://www.nature.com/articles/s42255-022-00568-y

Dr. **Jian-Jian Li** at the University of California Davis discovered that radiation-enhanced fatty acid metabolism boosts immune check protein CD47 overexpression that enhances tumor response to checkpoint targeted immunotherapy. A glycolysis-to-fatty acid oxidation (FAO) metabolic shifting is observed with induction of CD47, an immune checkpoint protein signaling "do not each me" against macrophage phagocytosis. He further demonstrated that inhibition of FAO by CPT1 inhibitor etomoxir or CRISPR-mediated deletion of CPT1A, CPT2, or ACAD9 re-sensitizes GBM to radiation with enhanced macrophage phagocytosis. This work was published in ***Nature Communications***: https://www.nature.com/articles/s41467-022-29137-3

Dr. **Hua Lu** at Tulane University discovered that cancer-derived unusual mutant p53s with extended C-termini without any other point mutations in their DNA binding domains could suppress wild-type p53 functions, consequently promoting cancer cell growth and proliferation. This work was published in ***J Mol Cell Biol***. https://pubmed.ncbi.nlm.nih.gov/34918105/. Moreover, he found that p53 maintains synaptic functions and structures in adult mouse primary somatosensory cortical neurons by employing a green brain mouse line that loses two alleles of p53. https://pubmed.ncbi.nlm.nih.gov/35465090/

Dr. **Zhenghe John Wang** at Case Western Reserve University discovered that p85β translocates into the nucleus in cancer cells with a PIK3CA helical domain to stabilize EZH1 and EZH2, thereby enhancing H3K27Me3. He further demonstrated that a combinationof p110α inhibitor alpelisb and EZH2 inhibitor Tazemetostat induces regression of tumors with a PIK3CA helical domain mutation, which lays foundation for a clinical trial to enroll patients soon. This work was published in ***Nature Communications***. https://www.nature.com/articles/s41467-022-29585-x

Dr. **Erxi Wu** at Baylor Research has a highly productive year with six papers in various journals: 1) identification of the landmark multi-omics signatures that may serve as potential therapeutic targets in gliomas https://www.sciencedirect.com/science/article/pii/S2001037022002720; 2) designed a novel aptamer targeting RPS7 for rapid screening of bladder carcinoma https://www.journals.elsevier.com/genes-and-diseases; 3) discovered that gut dysbiosis in cryptogenic stroke patients was associated with the severity of cryptogenic stroke and the systemic inflammation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120915/pdf/fimmu-13-836820.pdf; 4) reviewed current literature in CAR-T therapies https://www.frontiersin.org/articles/10.3389/fimmu.2022.896685/full; 5) identified a small molecule targets SARS-CoV-2 and its Delta and Omicron variants https://

Members' Research Highlights (Cont'd)

www.ncbi.nlm.nih.gov/pmc/articles/PMC9181633/pdf/main.pdf; 6) identified BAG5 as a potential biomarker for Parkinson's disease patients with R492X PINK1 mutation https://www.frontiersin.org/articles/10.3389/fnins.2022.903958/abstract.

Dr. **Jindan Yu** at Northwestern University. We identify HDAC3 as a new protein partner of HOXB13, a transcription factor that is almost exclusively expressed in the prostate, suppresses de novo lipogenesis through recruiting HDAC3 for epigenetic remodeling of lipogenic enhancers. This function is disrupted by HOXB13 G84E mutation, a germline mutation that has been associated with early-onset, familial prostate cancer. Further, HOXB13 is lost in about 30% of metastatic castration-resistant prostate cancer, partially due to DNA methylation, leading to lipid accumulation and prostate cancer metastasis. This study was published in ***Nature Genetics*** https://pubmed.ncbi.nlm.nih.gov/35468964/.

Dr. **Lanjing Zhang** at Rutgers University and Penn Medicine Princeton Medical Center showed changing trends in the proportional incidence and five-year net survival of screened and non-screened breast cancers among women during 1995-2011 in England in ***J Clin Transl Pathol*** https://pubmed.ncbi.nlm.nih.gov/35403174/ . His team also reported multivariable-adjusted trends in mortality due to alcoholic liver disease among adults in the United States, from 1999-2017 in ***Am J Transl Res***. https://pubmed.ncbi.nlm.nih.gov/35273712/

Scan the QR code on the right

To join the ACACR annual seminar series at 3:00 pm EDT (2:00 pm CDT) , Fridays
https://pitt.zoom.us/j/3013277369
meeting ID: 301 327 7369
password: 393966

SCAN ME

Genes & Diseases
An international journal for molecular and translational medicine

Journal Metrics

CiteScore: 9.5 / 79.5% (2021)
Impact Factor: 7.243 (2021/2022)
Source Normalized Impact per Paper (SNIP): 1.563 (2021)
SCImago Journal Rank (SJR): 1.736 (2021)

Review Speed



Published Quarterly
Open Access
ISSN: 2352-3042

Types of Articles

Full length article, review article, short communication, correspondence, perspective, commentary, views on news, and research watch.

Call for Papers

Email: editor@genesndiseases.com
Home page: https://www.journals.elsevier.com/genes-and-diseases/
Journal page: https://www.sciencedirect.com/journal/genes-and-diseases

In partnership with ACACR

Northwestern University

Brain cancer post-doctoral scholar

Lab profile:
The Cheng Lab is a neuro-oncology lab with the aim of studying mechanisms that regulate phenotypes and therapy responses of brain cancer.

Looking for:
A Post-Doctoral researcher in the Northwestern University Feinberg School of Medicine, Dept of Neurology.

- Cheng lab is a highly productive and dynamic research team with an established track record of basic and translational research that seeks to mentor future faculty or other aspirations
- Cheng lab focuses on cancer stem cell biology, cellular signaling, RNA biology, therapy response and resistance in human brain tumors
- Research areas include, but are not limited to, RNA biology including circular RNAs, lncRNAs in cancer, use of multi-omics to identify novel targets or pathways to improve immunotherapy response, mechanisms of therapy resistance. However, self-driven, capable, and independent postdocs can develop his/her own project on brain tumors
- Benefits are included as well as competitive compensation packages.

Location:
Located in downtown Chicago, IL, Northwestern University allows the best of both worlds of a tightknit community but also world-renown art, food, and culture. Chicago also boasts an international airport, the scenic Lake Michigan, and architecture that rivals any other city.

Lab life:
The Cheng Lab is dedicated to helping all mentees succeed. Whether it's celebrating a new paper or grant, or simply acknowledging an experimental success, our collaborative and supportive environment is instrumental in the lab's overall success. We are seeking like-minded and collaborative individuals to continue enhancing our group!

Contact: shiyuan.cheng@northwestern.edu for more information today!

https://labs.feinberg.northwestern.edu/cheng/



DEPARTMENT OF NEUROSURGERY

Baylor Scott & White HEALTH

Texas A&M HEALTH SCIENCE CENTER

LIVESTRONG CANCER INSTITUTES

Erxi Wu Lab recuits a postdoctoral follow

The vision of Neuroscience Institute at Baylor Scott & White Health, Temple, TX, directed by Dr. Jason H. Huang, is to search for novel and effective therapeutic intervention strategies for neuro-oncological diseases such as brain tumors and related diseases through science, scholarship, and innovation. Our overarching goal is to translate laboratory findings into the development of new therapeutic strategies. We are currently seeking a highly motivated postdoctoral researcher to work on projects examining the molecular events that regulate cancers such as brain tumors and pancreatic cancer and neuro-degenerative diseases such as Alzheimer disease. Candidates should have a Ph.D. or M.D. degree with experience and knowledge in cancer biology, molecular biology, and pharmacology or neuroscience and dedication to scholarly research. Candidates are expected to be able to use in vitro approaches and live animal models as well as human subjects to investigate and characterize the signaling mechanisms in the diseases. Candidates with demonstrated organizational skills, excellent communication skills, and the ability to work independently and in a collaborative, team environment are preferred. The successful applicants will have ample opportunities to develop new skills, and work in an excellent scientific environment with full access to cutting edge tools and technologies. This is an ideal opportunity for these enthusiastic, committed biologists to make an important contribution to rationale therapeutics targets for cancer and neuroscience. Candidates are interested in this opportunity, please contact Dr. Erxi Wu at Erxi.Wu@BSWHealth.org with your CV and cover letter. You can also call 254-724-3785/617-319-4193 for informal inquiry about this position.

Please go to the job link to fill in your application using the number ID: 22013306 (search the number) : http://jobs.bswhealth.com/career-areas/

5701 Airport Road | D123 | Temple, Texas 76502 Tel: 254.724.3785

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Postdoctoral Researcher

Dr. Jenny Wang (https://medicine.osu.edu/cancer-biology-genetics/directory/faculty/wang-jenny-phd/pages/index.aspx), a professor at Department of Cancer Biology and Genetics, The Ohio State University Wexner Medical Center invites applications for full-time researchers at the level of **Postdoctoral Researcher**. **We are looking for** scientists with a doctoral degree, outstanding academic credentials and a record of scholarly productivity in the areas of tumor biology, immunology and genetics. Successful candidates will conduct research to determine molecular mechanisms of colon cancer immune evasion, metastasis, tumor dormancy and drug resistance, identify and validate novel targets using 2D- and 3D- cell cultures, mouse models and PDXs, and ultimately develop effective therapies to treat colon cancer patients. **The Ohio State University offers a competitive salary and outstanding benefits**.

The Ohio State University is one of the largest public universities with 200+ academic majors, significant physical and interdisciplinary interactions between the Colleges of Arts and Sciences and Medicine. This is complemented by an outstanding Comprehensive Cancer Center, which provides the infrastructure and resources for strong interdisciplinary interactions with a focus on translation, in a collegial and supportive research environment. The university is located in Columbus, a vibrant and rapidly developing city of almost one million, which is recognized by Money Magazine as one of the "6 best big cities" in the US.

The Ohio State University is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status or protected veteran status.

Applications should include *Curriculum Vitae*, Research Summary, and contact information for three academic references and be sent to jing.wang@osumc.edu.

How to become a member of ACACR 如何成为ACACR 协会会员

感谢大家对ACACR 的关心和鼓励，更感谢许多志愿者们的付出。我们的财务李勇已把协会的银行帐户，PayPal 帐户开好；我们 IT 小组的戴木水已经将网上自动付款体系建成。下面是如何成为我们协会成员了。

我们有两种会员制，普通会员（regular member) 和 临时会员（associate member)。普通会员又分终生会员（lifetime membership) 以及年度会员， 前者会费 $500, 后者会费每两年$100。临时会员暂不收费，但以后可能会有所改变。

目前我们还是半自动化注册（即有部分是手工）。请到我们网站 acacr.org 在"membership"栏下载注册表，填好后电邮给表最后的邮件地址。

我们共有三种付会员费的方式：

1. 在我们网站上用Paypal(或信用产卡）付tacacr@outlook.com
2. 银行直接Transfer Money (Zelle, like Chase Quickpay) to tacacr@outlook.com.
3. 支票. 请写明付给 "Association of Chinese Americans in Cancer Research, Inc." 需要邮寄支票的， 请与Dr. Yong Li 联系， Yong.Li@bcm.edu， 请在电邮上注明 ACACR member.

我们将在收到付款后五-七个工作日发出收据。

协会会员的益处：

协会普通会员和临时会员都可以参加WeChat 的讨论，信息交流，年会以及其他一些由ACACR 组织的活动。普通会员还有以下一些额外的福利。

（1）协会内部选举和被选举权；
（2）由ACACR 推荐去AACR 各种委员会和杂志编辑部；
(3）在我们协会网站上招人广告栏上发广告（微信群里的帖子会很快被淹没）；
（4）在我们协会网站上贴一些会议通知；
（5）在我们协会每月一次的 Newsletter 上登广告（非会员收费 $20);
（6）我们协会网站和 Newsletter "Research Highlights" 栏目中将优先选发协会会员刚发表的文章；
（7）今后ACACR 有小型奖励机会（award opportunity), 将优先考虑我们的普通会员；
(8) 今后购买ACACR 赞助商的物品时可能有折扣机会。

普通会员今后可能有的福利还包括会员学术交流活动（annual retreat), 成员互助等。

Association of Chinese Americans in Cancer Research

SCAN me to join the ACACR

2022 Annual Seminar Series

When: Every Friday 3:00 pm EST (2:00 pm CST, 1:00 pm MST and 12:00 pm pm PST) starting from July 8, 2022

Zoom link:
https://pitt.zoom.us/j/3013277369

meeting ID: 301 327 7369
password: 393966

2022 ACACR Virtual Seminar Series Committee
Gensheng Feng, PhD (Chair)
Lin Zhang, PhD
Shiyuan Cheng, PhD
Zhenkun Lou, PhD
Yong Li, PhD
Erxi Wu, PhD

Date	1st Speaker (3:00-3:30 pm EST)	2nd Speaker (3:40-4:10 pm EST)	Hosts
8-Jul	Yi Zhang, Harvard	Jiefu Li, Janelia Farm/HHMI	Gensheng Feng/Shiyuan Cheng
15-Jul	Shiyong Sun, Emory	Peter Wang, USC	Yong Li/Emily Wang
22-Jul	Zhaodong Li, Cancer Cell; Ioanna Pavlaki, Nature Cancer; Di Jiang, Science		Gensheng Feng/, Lin Zhang
29-Jul	Rugang Zhang, Wistar	Xin Chen, Hawaii	Shiyuan Cheng/Bangyan Stiles
5-Aug	Huiping Liu, North-western	Ping Mu, UT Southwestern	Shiyuan Cheng/Zhenkun Lou
12-Aug	Jun-Lin Guan, Cincinnati	Hao Yan, Arizona State	Erxi Wu/Lin Zhang
19-Aug	Sidi Chen, Yale	Ting Wang, Wash U	Erxi Wu/Shiyuan Cheng
26-Aug	Xi Chen, Baylor	Yiping He, Duke	Zhenkun Lou/Shiyuan Cheng

Association of Chinese Americans in Cancer Research

Annual Meeting Virtual Seminar Series

Friday, July 22, 2022

3:00-3:20 PM EST

Di Jiang, PhD

Senior Editor, Science/AAAS

"Publishing in Science: an Inside Look"

3:20-3:40 PM EST

Ioanna Pavlaki, PhD

Associate Editor, Nature Cancer

"The insider's guide to Nature Cancer"



3:40-4:00 PM EST

Zhaodong Li, PhD

Scientific Editor, Cancer Cell

"Publishing with Cancer Cell"

4:00-4:30 PM EST

Q&A/Panel Discussion

Zoom Link: https://pitt.zoom.us/j/3013277369

Meeting ID: 301 327 7369; Password: 393966

Host: Gen-Sheng Feng, PhD and Lin Zhang, PhD

Association of Chinese Americans in Cancer Research

Annual Meeting Virtual Seminar Series

Friday, July 15th, 2022

3:00-3:30 PM EST

Shi-Yong Sun, Ph.D.

Professor and Halpern Research Scholar, Emory University

"Managing acquired resistance to third generation EGFR-TKIs"

3:40-4:10 PM EST

Yingxiao Wang, PhD



Professor, University of California, San Diego

"Engineering Ultrasound-Controllable Genetics and Cells for Cancer Immunotherapy"

Zoom Link:

https://pitt.zoom.us/j/3013277369

Meeting ID: 301 327 7369; Password: 393966

Host: Yong Li, Ph.D. and Lingyan Shi, Ph.D.

Association of Chinese Americans in Cancer Research

Annual Meeting Virtual Seminar Series

Friday, July 29th, 2022

3:00-3:30 PM EST

Xin Chen, PhD

Professor, University of Hawaii Cancer Center

"Preclinical studies of liver tumor development: how to dissect signaling pathways *in vivo*"

3:40-4:10 PM EST

Rugang Zhang, PhD

Professor, The Wistar Institute

"ADAR1, Autophagy and Cellular Senescence - Implications for Tissue Aging and Cancer"

Zoom Link:

https://pitt.zoom.us/j/3013277369

Meeting ID: 301 327 7369; Password: 393966

Host: Shiyuan Cheng, PhD and Bangyan Stiles, PhD

Association of Chinese Americans in Cancer Research

Annual Meeting Virtual Seminar Series

Friday, Aug 5th, 2022



3:00-3:30 PM EST

Huiping Liu, MD, PhD

Associate Professor, Northwestern University

"Machine learning in understanding and targeting circulating tumor stem cell clusters"

3:40-4:10 PM EST

Ping Mu, PhD

Assistant Professor, UT Southwestern Medical Center

"The Two Faces of Cancer: Plasticity and Heterogeneity"

Zoom Link:

https://pitt.zoom.us/j/3013277369

Meeting ID: 301 327 7369; Password: 393966

Host: Shiyuan Cheng, PhD and Zhenkun Lou, PhD

Volume 2, Issue 8 February 2022

ASSOCIATOIN OF CHINESE AMERICANS IN CANCER RESEARCH

PO Box 1382,
Timonium, MD 21093

Phone: (443) 923-9498
Email: acacr@weebly.com

We are on the web http://www.acacr.org/

Our Missions

Our mission is to prevent and cure cancer through fostering interactions and collaborations among Chinese Americans in all areas of cancer research including cancer biology, etiology, genetics, epidemiology, prevention, diagnosis, and treatment. ACACR also promotes interactions and collaborations among professionals of Chinese background and/or ethnicity in cancer research through the exchange of information in education, technology, employment, and business opportunities.

Wish You a Happy and Cool Summer!

Management team (web link)

Board of Directors
Shiyuan Cheng, PhD
Wei Gu, PhD
Yibin Kang, PhD
Jinsong Liu, MD, MA, PhD
Hua Lu, MD, PhD
Shaomeng Wang, PhD

President
Lin Zhang, PhD

President Elect
Gen-Sheng Feng, PhD

General Secretary
Erxi Wu, PhD

Treasurer
Yong Li, PhD

Committee chair/co-chair

Annual meeting
Gensheng Feng, PhD
Tongchuan He, MD, PhD
Binhua Zhou, MD, PhD

Audit
Zhaohui Feng, PhD

Fundraising
Bin Li, MD
Xing Fan, MD PhD

IT-support
Wenwei Hu, PhD
Mushui Dai, MD, PhD

Membership
Yaguang Xi, MD, PhD, MBA

Newsletters
Lanjing Zhang, MD
Shuhang Wang, MD

Past Presidents
2019-2021
Zhenkun Lou, PhD

2017-2018
Shiyuan Cheng, PhD

Call for submissions and volunteers

We would love to hear from you. Any suggestions or ideas are welcome. We also would like to invite you to join our newsletter team. If interested, please email lanjing.zhang@rutgers.edu

SCAN ME

To join ACACR annual seminar series